Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Capromorelin Tartrate

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Oral Solution Elanco US Inc. Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:40 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:40 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 22, 2026, 10:42 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:40 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Capromorelin Tartrate

Capromorelin Tartrate

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Oral Solution Rx required 100% reference complete

Species: Both

Manufacturer: Elanco US Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Capromorelin Tartrate

For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease. Species commonly shown: Both, Dog, Cat.

Generic name
Capromorelin Tartrate
Brand names
ENTYCE™, Elura™
Manufacturer
Elanco US Inc.
Species
Both, Dog, Cat
Dosage forms
Oral Solution
Prescription
Prescription required
Completeness
100%
Validation
Needs review
Brand names
ENTYCE™ Elura™
Dosage forms
Oral Solution

Indications / Uses

For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease.

Warnings / Contraindications

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

  • The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Side Effects

Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Diarrhoea.

FAQ

Both, Dog, Cat

Yes. Roxee shows this as prescription-only.

Oral Solution

Related Conditions

Chronic Kidney Disease (CKD) Weight loss

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For appetite stimulation in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches
  • wobbly/unsteady walking (1 reports)
  • Decreased red blood cell count (1 reports)
  • Decreased packed cell volume (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Capromorelin Tartrate; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-070810
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 29 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-070810
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-070810
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Decreased red blood cell count (1 reports), Decreased packed cell volume (1 reports), Decreased haematocrit (1 reports), Decreased body temperature (1 reports)

Body systems represented Signal grouping

Digestive (2), Neurologic (1), Behavior (1), Other (28)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (21 reports), Dog (11 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (2), ['Siberian Husky', 'Dog (unknown)'] (1), Cat (unknown) (1), ['Chihuahua', 'Dog (unknown)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Capromorelin Tartrate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bit, wobbly/unsteady walking, Decreased red blood cell count, Decreased packed cell volume

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Capromorelin Tartrate brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-070810 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 16, 2026, 10:08 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches
  • wobbly/unsteady walking
  • Decreased red blood cell count
  • Decreased packed cell volume

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Decreased red blood cell count (1 reports)
  • Decreased packed cell volume (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat, Dog
Indication / use
For appetite stimulation in dogs.
Form / route / dose
Form: Oral Solution
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Elanco US Inc.
Form: Oral Solution
Identifiers:
NADA: 141457 NADA: 141536 NDC Package: 58198-5535-1 NDC Package: 58198-5535-2 NDC Package: 58198-5535-3 NDC Product: 58198
Source metadata:

Warnings / Contraindications

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

  • High: The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
22
Matching reports
4
Active filters
1
Selected filters
Reaction: Abnormal radiograph finding Clear
Reset
Drill into common report signals
Death (5) Diarrhoea (5) Lack of efficacy - NOS (5) Abnormal radiograph finding (4) Other (17) Digestive (13) Neurologic (7) Effectiveness (5)
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-074690

Received 2025-12-09 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
Under 10 lb (4.2 Kilogram)
Age
1-3 years (2.2 Year)
Sex
Female Neutered
Region
USA
Reactions
Not eatingHidingFeverPyrexiaEmesis (multiple)Low platelet countPlatelet disorder NOSHyperglycaemiaDistressHypothyroidismOther abnormal test result NOSProteinuriaBilirubinuriaTarry or black stool (see also haemorrhagic diarrhoea)Behavioural disorder NOSWarm feeling to the touchReddening of the skinAbnormal radiograph findingDistension of abdomenPancreatitis NOSVomiting
Body systems
OtherDigestiveBehavior
Outcomes
Ongoing

USA-USFDACVM-2025-US-070810

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
['Shih Tzu', 'Spitz - German Pomeranian']
Size / weight
Under 10 lb (3.402 Kilogram)
Age
8+ years (8 Year)
Sex
Female Neutered
Region
USA
Reactions
Seizure NOSDeathMedication error NOSNot eatingLeucocytosis NOSPain NOSElevated lactateHyperglycaemiaAbdominal discomfortAbnormal radiograph findingNeutrophiliaMonocytosisElevated triglyceride
Body systems
NeurologicOther
Outcomes
Died

USA-USFDACVM-2025-US-072580

Received 2025-11-25 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Mediumhair
Size / weight
Under 10 lb (4.13 Kilogram)
Age
1-3 years (2 Year)
Sex
Female Neutered
Region
USA
Reactions
Reluctant to moveVocalisationLoss of bowel controlNot urinatingEosinopeniaBasophiliaHypernatremiaThrombocytopeniaAbnormal radiograph findingThird eyelid protrusionOther ear disorder NOSNasal dischargeFalling
Body systems
Other
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-068768

Received 2025-11-14 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Mediumhair
Size / weight
Under 10 lb (4.13 Kilogram)
Age
1-3 years (2 Year)
Sex
Female Neutered
Region
USA
Reactions
AnorexiaReluctant to moveVocalisationLoss of bowel controlNot urinatingEosinopeniaBasophiliaHypernatremiaThrombocytopeniaAbnormal radiograph findingThird eyelid protrusionOther ear disorder NOS
Body systems
DigestiveOther
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
29
Species represented
2
Grouped by Body System
Digestive (2) · Loss of appetite, Decreased appetite Neurologic (1) · Unsteady walking (ataxia) Behavior (1) · Behavioral disorder (unspecified) Other (28) · Decreased red blood cell count, Decreased packed cell volume, Decreased haematocrit
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Digestive 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Cat (21) Dog (11)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Digestive Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

ENTYCE™ SPL · SPL Elura™ SPL · SPL UCM504544.pdf FOI · FOI

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

2

ENTYCE™

SPL · SPL

Open original
FDA Structured Product Label

ENTYCE™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
NADA
141-457
Status
RX
Form
Oral Solution
Route
Oral
Species
Dog
Composition / specifications
Each milliliter of solution contains 30 milligrams (mg) capromorelin.

Dogs

Indication
For appetite stimulation in dogs.
Dosage
Administer 3 mg/kg once daily by mouth.
Limitations
The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Elura™

SPL · SPL

Open original
FDA Structured Product Label

Elura™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
NADA
141-536
Status
RX
Form
Oral Solution
Route
Oral
Species
Cat
Composition / specifications
20 mg/mL flavored oral solution

Cats

Indication

For management of weight loss in cats with chronic kidney disease.

Dosage

2 mg/kg once daily

UCM504544.pdf

FOI · FOI

Open original

FOI Summary oN 141-536 Approved October 16, 2020.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:40 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Oral Solution • Oral
Applications: NADA 141-457 • NADA 141-536
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 50 • Cat 83 • View
Case summaries: 22 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: N18.9
Chronic kidney disease, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Decreased red blood cell count (1) Decreased packed cell volume (1) Decreased haematocrit (1) Decreased body temperature (1) Decreased appetite (1) Death by euthanasia (1) Death (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141457 NADA: 141536 NDC Package: 58198-5535-1 NDC Package: 58198-5535-2 NDC Package: 58198-5535-3 NDC Product: 58198
Package NDC Product NDC Form / Route Status
58198-5535-1 58198 -
58198-5535-2 58198 -
58198-5535-3 58198 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 12 Clinical 4 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Clinical, 2026-04-11)
  • usage: For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease. (Clinical, 2026-04-17)
  • contraindications: The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches. (Official, 2026-04-22)
  • contraindications: The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches. (Official, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Official, 2026-04-17)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Official, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'… (Official, 2026-02-12)
  • usage: For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease. (Official, 2026-04-22)
  • usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-16)
  • usage: For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease. (Official, 2026-04-16)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-17 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-17 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-17 10:05 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 10:08 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
ENTYCE™
RX
Capromorelin
Oral Solution • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-457 Approved Nov 19, 2020
Elura™
RX
Capromorelin
Oral Solution • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-536 Approved Oct 16, 2020

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Each milliliter of solution contains 30 milligrams (mg) capromorelin.
Dogs
Indication
For appetite stimulation in dogs.
Dosage
Administer 3 mg/kg once daily by mouth.
Limitations
The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

FDA page: Open in Animal Drugs @ FDA

Species: Cat
Composition / specifications
20 mg/mL flavored oral solution
Cats
Indication

For management of weight loss in cats with chronic kidney disease.

Dosage

2 mg/kg once daily

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

For appetite stimulation in dogs. For management of weight loss in cats with chronic kidney disease.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Decreased appetite (1) • Cat

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Decreased red blood cell count (1) • Cat Decreased packed cell volume (1) • Cat Decreased haematocrit (1) • Cat Decreased body temperature (1) • Cat Death by euthanasia (1) • Cat
Show more (23)
Death (1) • Cat Cyst NOS (1) • Cat Crackles on auscultation (1) • Dog Cough (1) • Dog Corneal oedema (1) • Dog Conjunctival oedema (1) • Dog Cold feeling to the touch (1) • Cat Cardiac enlargement (1) • Cat Bloody stool (1) • Cat Bloodshot eye (1) • Dog Bloated stomach (1) • Cat Bilirubinuria (1) • Cat Basophilia (1) • Cat Barking (1) • Dog Bacterial skin infection NOS (1) • Dog Ascites (1) • Cat Arthritis (1) • Cat Aortic mineralisation (1) • Cat Anaemia NOS (1) • Cat Acidosis (1) • Cat Abnormal Schirmer tear test (1) • Dog Abnormal radiograph finding (1) • Cat Abdominal discomfort (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Shorthair, Female, 10 year, 4.85 kilogram • Drug: MSK, Solution, Oral • Reactions: Heart murmur, High ionized calcium, Cyst NOS, Aortic mineralisation, Not eating… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075006
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 4.850 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
Reactions Reported:
Heart murmur High ionized calcium Cyst NOS Aortic mineralisation Not eating Third eyelid protrusion Pawing Mental impairment NOS Hypotension Decreased packed cell volume
Outcomes: Ongoing

Dog, ['Siberian Husky', 'Dog (unknown)'], Male, 2 year, 22 kilogram • Drug: MSK, Solution, Oral, Dose: 3 Milligram per kilogram, Frequency: 1 per day • Reactions: Diarrhea • Outcome: Recovered/Normal

  • Report ID: CAN-USFDACVM-2025-CA-000113
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 2.00 Year
  • Weight: 22.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
  • Dose: 3 Milligram per kilogram
  • Frequency: 1 per day
Reactions Reported:
Diarrhea
Outcomes: Recovered/Normal

Cat, Cat (unknown), Unknown • Drug: MSK, Solution, Oral • Reactions: Drooling, Nausea • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-074788
  • Serious AE: No
  • Treated For AE: No
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
Reactions Reported:
Drooling Nausea
Outcomes: Recovered/Normal

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 20 week, 2.26 kilogram • Drug: MSK, Solution, Oral • Reactions: Icterus, Death, Other abnormal test result NOS, Elevated liver enzymes NOS, Swollen joint… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074897
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 20.00 Week
  • Weight: 2.260 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
Reactions Reported:
Icterus Death Other abnormal test result NOS Elevated liver enzymes NOS Swollen joint Localised hair loss Skin lesion NOS Conjunctival oedema Corneal oedema Skin scab Swollen limb Tiredness (lethargy) Loss of appetite Ear infection NOS Local swelling
Outcomes: Died

Dog, Collie - Border, Female, 11 year, 17.23 kilogram • Drug: MSK, Solution, Oral, Dose: 1.60 mL per animal, Frequency: 1 per day • Reactions: Gagging, Drooling, Arthritis, UNPALATABLE, Medication error NOS… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-073622
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 17.230 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
  • Dose: 1.60 mL per animal
  • Frequency: 1 per day
Reactions Reported:
Gagging Drooling Arthritis UNPALATABLE Medication error NOS INEFFECTIVE, OTHER DRUG
Outcomes: Outcome Unknown

Cat, Domestic Mediumhair, Female, 2 year, 4.627 kilogram • Drug: MSK, Liquid, Oral • Reactions: Vomiting, Not eating, Hiding, Hyperglycaemia, Fever… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072755
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.00 Year
  • Weight: 4.627 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Liquid
Reactions Reported:
Vomiting Not eating Hiding Hyperglycaemia Fever Tachycardia Tachypnoea Bloody stool Weight loss Gall bladder & bile duct disorder NOS Gastric distension Intestinal thickening Diarrhea
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 2.2 year, 4.2 kilogram • Drug: MSK, Solution, Unknown, Dose: 0.45 mL per animal • Reactions: Not eating, Hiding, Fever, Vomiting, Low platelet count… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074690
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.20 Year
  • Weight: 4.200 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Solution
  • Dose: 0.45 mL per animal
Reactions Reported:
Not eating Hiding Fever Vomiting Low platelet count Platelet disorder NOS Hyperglycaemia Distress Hypothyroidism Other abnormal test result NOS Proteinuria Bilirubinuria Tarry or black stool Behavioral disorder (unspecified) Warm feeling to the touch Reddening of the skin Abnormal radiograph finding Distension of abdomen Pancreatitis NOS
Outcomes: Ongoing

Dog, Terrier - Yorkshire, Female, 13.5 year, 2.8 kilogram • Drug: MSK, Solution, Oral, Dose: 2 mL per animal • Reactions: Pale mucous membrane, Laboured breathing, Increased respiratory rate, Crackles on auscultation, Prolonged capillary refill time… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072177
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.50 Year
  • Weight: 2.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Solution
  • Dose: 2 mL per animal
Reactions Reported:
Pale mucous membrane Laboured breathing Increased respiratory rate Crackles on auscultation Prolonged capillary refill time Other abnormal test result NOS
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.